Clark Distelhorst, MD
Clark Distelhorst, MD is the Charles S. Britton II Professor of Hematology and Oncology at the Case Western Reserve University School of Medicine and the Co-Director of the Basic Research Program at the Case Comprehensive Cancer Center.
Inspired by the amazing therapeutic success of corticosteroid treatment in children with acute lymphoblastic leukemia, Dr. Distelhorst set out to understand how corticosteroid hormones kill leukemia cells. An unanticipated byproduct of this research was his lab’s discovery that the cancer-related Bcl-2 protein, which causes therapeutic resistance to corticosteroids and other chemotherapeutic agents, does so in part by binding to and regulating an intracellular calcium channel, the inositol 1,4,5- trisphosphate receptor.
Understanding this fundamental mechanism provided Dr. Distelhorst the unique opportunity to develop a new treatment strategy for Bcl-2- associated cancers. As a first step his laboratory developed a novel Bcl-2 inhibitor. Now, with the help and guidance of the Harrington Discovery Institute, Dr. Distelhorst is poised to take this inhibitor from the laboratory into the clinic as a novel drug to treat cancer.
Dr. Distelhorst was awarded BA and M. degrees Summa Cum Laude from The Ohio State University. He trained in Internal Medicine at the Yale-New Haven Hospital and Barnes Hospital/Washington University School of Medicine in St. Louis. Dr. Distelhorst is a member of the Association of American Physicians and The American Society for Clinical Investigation.